403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
AVACEN Medical Issued U.S. Patent For CATHSTATM Large-Bore Catheter Stabilization Device
(MENAFN- EIN Presswire) EINPresswire/ -- AVACEN, Inc., a leader in non-invasive and access-adjacent medical device innovation, today announced the issuance of a U.S. utility patent for its CATHeter STAbilization (CATHSTATM) device.
CATHSTATM is designed for high-acuity applications requiring secure large-bore vascular access, including transcatheter cardiac interventions, mechanical circulatory support, indwelling, extracorporeal membrane oxygenation (ECMO), and renal replacement therapies.
The CATHSTATM system provides angle-adaptive mechanical stabilization for large-bore arterial access, helping reduce catheter migration and access-site stress during complex and prolonged procedures. The technology is protected by U.S. Patent No. 12,447,315.
From a commercial perspective, CATHSTATM combines a low-COGS, high-margin disposable model with a workflow-neutral design, enabling adoption without procedural disruption or capital investment. The product is intended to scale efficiently through existing global hospital procedural sales channels.
“We are selectively initiating strategic discussions around potential acquisition, licensing, or manufacturing and distribution partnerships for CATHSTATM,” said Thomas Muehlbauer, CEO of AVACEN.“CATHSTATM addresses a rapidly expanding market with an expected CAGR approaching 10%, which materially enhances the long-term strategic value of the issued patent.”
About AVACEN, Inc.
AVACEN (Advanced VAscular Circulation ENhancement) develops and markets innovative, non-invasive medical devices designed to enhance microcirculation and support procedural precision. Based in Carlsbad, California, AVACEN is committed to improving patient outcomes through scientifically supported, patent-protected technologies.
CATHSTATM is designed for high-acuity applications requiring secure large-bore vascular access, including transcatheter cardiac interventions, mechanical circulatory support, indwelling, extracorporeal membrane oxygenation (ECMO), and renal replacement therapies.
The CATHSTATM system provides angle-adaptive mechanical stabilization for large-bore arterial access, helping reduce catheter migration and access-site stress during complex and prolonged procedures. The technology is protected by U.S. Patent No. 12,447,315.
From a commercial perspective, CATHSTATM combines a low-COGS, high-margin disposable model with a workflow-neutral design, enabling adoption without procedural disruption or capital investment. The product is intended to scale efficiently through existing global hospital procedural sales channels.
“We are selectively initiating strategic discussions around potential acquisition, licensing, or manufacturing and distribution partnerships for CATHSTATM,” said Thomas Muehlbauer, CEO of AVACEN.“CATHSTATM addresses a rapidly expanding market with an expected CAGR approaching 10%, which materially enhances the long-term strategic value of the issued patent.”
About AVACEN, Inc.
AVACEN (Advanced VAscular Circulation ENhancement) develops and markets innovative, non-invasive medical devices designed to enhance microcirculation and support procedural precision. Based in Carlsbad, California, AVACEN is committed to improving patient outcomes through scientifically supported, patent-protected technologies.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment